Related Experiment Video
Updated: Jun 30, 2025
Expression, Purification, and Antimicrobial Activity of S100A12
Published on: May 13, 2017
Advances in the study of S100A9 in cardiovascular diseases
Fengling Chen1,2, Ziyu He2, Chengming Wang2
1Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Insights
S100A9 protein is a key biomarker for diagnosing and predicting cardiovascular diseases (CVD). Understanding its role in inflammation, fibrosis, and vascular dysfunction offers new therapeutic targets for CVD.
Area of Science:
- Biochemistry
- Cardiology
- Immunology
Background:
- Cardiovascular diseases (CVD) present significant global health challenges, characterized by inflammation, oxidative stress, and fibrosis.
- S100A9, a calcium-binding protein secreted by myeloid cells, interacts with key receptors (TLR4, RAGE) and influences CVD-related pathological processes.
- Current research highlights S100A9's potential as a crucial biomarker for CVD diagnosis and prognosis.
Purpose of the Study:
- To review the latest advancements in the diagnostic, predictive, and therapeutic applications of S100A9 in inflammatory CVD.
- To elucidate the molecular mechanisms underlying S100A9's role in the progression of atherosclerosis, myocardial infarction, and arterial aneurysms.
- To identify novel predictive strategies and potential therapeutic targets for cardiovascular diseases.
Main Methods:
- Literature review of recent research on S100A9 and cardiovascular diseases.
- Analysis of S100A9's molecular interactions and signaling pathways in CVD pathogenesis.
- Synthesis of findings related to S100A9's biomarker potential and therapeutic implications.
Main Results:
- S100A9 is implicated in inflammatory responses, fibrosis, vascular calcification, and endothelial barrier dysfunction in CVD.
- S100A9 demonstrates significant potential as a diagnostic and predictive biomarker across various CVD types.
- The protein's molecular mechanisms offer insights into disease progression and potential intervention points.
Conclusions:
- S100A9 plays a critical role in the pathogenesis of inflammatory cardiovascular diseases.
- S100A9 serves as a promising biomarker for early detection and risk stratification of CVD.
- Targeting S100A9 pathways may offer novel therapeutic strategies for managing cardiovascular conditions.
Abstract:
Cardiovascular disease (CVD) is a group of diseases that primarily affect the heart or blood vessels, with high disability and mortality rates, posing a serious threat to human health. The causative factors, pathogenesis, and characteristics of common CVD differ, but they all involve common pathological processes such as inflammation, oxidative stress, and fibrosis. S100A9 belongs to the S100 family of calcium-binding proteins, which are mainly secreted by myeloid cells and bind to the Toll-like receptor 4 and receptor for advanced glycation end products and is involved in regulating pathological processes such as inflammatory response, fibrosis, vascular calcification, and endothelial barrier function in CVD. The latest research has found that S100A9 is a key biomarker for diagnosing and predicting various CVD. Therefore, this article reviews the latest research progress on the diagnostic and predictive, and therapeutic value of S100A9 in inflammatory-related CVD such as atherosclerosis, myocardial infarction, and arterial aneurysm and summarizes its molecular mechanisms in the progression of CVD, aiming to explore new predictive methods and to identify potential intervention targets for CVD in clinical practice.
